Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIODESIX INCBDSX · Entity 6053 | Director | January 02, 2026 | January 06, 2026 |
| GenMark Diagnostics, Inc.GNMK · Entity 140086 | SVP, Research & Development | February 02, 2018 | February 06, 2018 |
| Inhibrx Biosciences, Inc.INBX · Entity 4576 | Director | September 23, 2026 | September 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIODESIX INC
Report date January 02, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 5,443 |
Reported balance
After 2026-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 5,443 · Balance 5,443 F1: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock ("Common Stock"). F2: These RSUs vest in four substantially equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F3: Represents deferred RSUs. The shares of Common Stock underlying these RSUs will be issued to the Reporting Person following the Reporting Person's separation from service with the Issuer. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.46 · Expires 2036-01-01 | Direct | 6,354 |
Reported balance
After 2026-01-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-02 · Grant · Acquired 6,354 · Balance 6,354 F4: This option vests in four substantially equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to the Reporting Person's continued service with the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock ("Common Stock").
F2: These RSUs vest in four substantially equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.
F3: Represents deferred RSUs. The shares of Common Stock underlying these RSUs will be issued to the Reporting Person following the Reporting Person's separation from service with the Issuer.
F4: This option vests in four substantially equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to the Reporting Person's continued service with the Issuer.
GenMark Diagnostics, Inc.
Report date February 02, 2018 · Filed February 06, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 197,622 |
Reported balance
After 2018-02-02 transaction · row 1
1 source rowRow 1 · 2018-02-02 · Sale · Disposed 148 · Balance 197,622 F1: The shares were sold pursuant to pre-established trading instructions solely to satisfy tax withholding obligations in connection with the partial vesting of previously granted restricted stock units. |
| Common StockSEC Table I · non-derivative | IndirectHI Charitable Remainder Uni Trust | 55,901 |
Reported balance
Holding disclosure · report date 2018-02-02 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 55,901 F2: The reporting person transferred 5,750 shares of the Issuer's common stock from the HI Charitable Remainder Trust to The Jon Faiz Kayyem and Paige N. Gates Family Trust. F3: Dr. Kayyem is the trustee of the HI Charitable Remainder Uni Trust, trustee of The Jon Faiz Kayyem and Paige N. Gates Family Trust, dated April 1, 2000 and the President of In-Motion LLC, the general partner of IFIN LP. Dr. Kayyem disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein. |
| Common StockSEC Table I · non-derivative | IndirectThe Jon Faiz Kayyem and Paige N. Gates Family Trust, dated April 1, 2000 | 88,684 |
Reported balance
Holding disclosure · report date 2018-02-02 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 88,684 F2: The reporting person transferred 5,750 shares of the Issuer's common stock from the HI Charitable Remainder Trust to The Jon Faiz Kayyem and Paige N. Gates Family Trust. F3: Dr. Kayyem is the trustee of the HI Charitable Remainder Uni Trust, trustee of The Jon Faiz Kayyem and Paige N. Gates Family Trust, dated April 1, 2000 and the President of In-Motion LLC, the general partner of IFIN LP. Dr. Kayyem disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein. |
| Common StockSEC Table I · non-derivative | IndirectIFIN LP | 569,308 |
Reported balance
Holding disclosure · report date 2018-02-02 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 569,308 F3: Dr. Kayyem is the trustee of the HI Charitable Remainder Uni Trust, trustee of The Jon Faiz Kayyem and Paige N. Gates Family Trust, dated April 1, 2000 and the President of In-Motion LLC, the general partner of IFIN LP. Dr. Kayyem disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were sold pursuant to pre-established trading instructions solely to satisfy tax withholding obligations in connection with the partial vesting of previously granted restricted stock units.
F2: The reporting person transferred 5,750 shares of the Issuer's common stock from the HI Charitable Remainder Trust to The Jon Faiz Kayyem and Paige N. Gates Family Trust.
F3: Dr. Kayyem is the trustee of the HI Charitable Remainder Uni Trust, trustee of The Jon Faiz Kayyem and Paige N. Gates Family Trust, dated April 1, 2000 and the President of In-Motion LLC, the general partner of IFIN LP. Dr. Kayyem disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein.
Inhibrx Biosciences, Inc.
Report date September 23, 2026 · Filed September 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy The Jon F. Kayyem and Paige Gates-Kayyem Family Trust | 434,360 |
Reported balance
After 2026-09-23 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-09-23 · Purchase · Acquired 5,000 · Balance 434,360 F1: These securities are directly owned by The Jon F. Kayyem and Paige Gates-Kayyem Family Trust. Jon Faiz Kayyem is the trustee of The Jon Faiz Kayyem and Paige N. Gates Family Trust and he disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Jon Faiz Kayyem Revocable Trust | 250,000 |
Reported balance
Holding disclosure · report date 2026-09-23 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 250,000 F2: These securities are directly owned by the Jon Faiz Kayyem Revocable Trust, of which Jon Faiz Kayyem is the trustee. |
| Common StockSEC Table I · non-derivative | IndirectBy Paige Gates-Kayyem Revocable Trust | 250,000 |
Reported balance
Holding disclosure · report date 2026-09-23 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 250,000 F3: These securities are directly owned by the Paige-Gates Kayyem Revocable Trust, of which Jon Faiz Kayyem's spouse is the trustee. |
| Common StockSEC Table I · non-derivative | IndirectBy Child A | 69,843 |
Reported balance
Holding disclosure · report date 2026-09-23 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 69,843 F4: These securities are directly owned by a custodial account managed by the reporting person for the benefit of the reporting person's minor child, Child A. The reporting person disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Child B | 69,843 |
Reported balance
Holding disclosure · report date 2026-09-23 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 69,843 F5: These securities are directly owned by a custodial account managed by the reporting person for the benefit of the reporting person's minor child, Child B. The reporting person disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein. |
Filing footnotes · ownership attribution and instrument terms
F1: These securities are directly owned by The Jon F. Kayyem and Paige Gates-Kayyem Family Trust. Jon Faiz Kayyem is the trustee of The Jon Faiz Kayyem and Paige N. Gates Family Trust and he disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein.
F2: These securities are directly owned by the Jon Faiz Kayyem Revocable Trust, of which Jon Faiz Kayyem is the trustee.
F3: These securities are directly owned by the Paige-Gates Kayyem Revocable Trust, of which Jon Faiz Kayyem's spouse is the trustee.
F4: These securities are directly owned by a custodial account managed by the reporting person for the benefit of the reporting person's minor child, Child A. The reporting person disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein.
F5: These securities are directly owned by a custodial account managed by the reporting person for the benefit of the reporting person's minor child, Child B. The reporting person disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Inhibrx, Inc.
Report date May 30, 2024 · Filed May 30, 2024
Section 16 reporting ended · disclosed 2024-05-30. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy The Jon F. Kayyem and Paige Gates-Kayyem Family Trust | 0 |
Reported balance
After 2024-05-30 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2024-05-30 · Disposition to issuer · Disposed 3,224,301 · Balance 0 F1: Under the Agreement and Plan of Merger, dated January 22, 2024 (the "Merger Agreement"), by and among the Inhibrx, Inc. (the "Issuer"), Aventis Inc., a Pennsylvania corporation ("Parent") and wholly owned subsidiary of Sanofi, and Art Acquisition Sub, Inc., a Delaware corporation ("Merger Sub") and wholly owned subsidiary of Parent, following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on May 30, 2024, Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F2: In the Merger, each share of common stock of the Issuer that was outstanding immediately prior to the effective time of the Merger (the "Effective Time") (other than (A) the Issuer's common stock owned by the Issuer as treasury shares, (B) the Issuer's common stock owned by Parent or Merger Sub and (C) any dissenting shares), was automatically cancelled, extinguished and converted into the right to receive (i) an amount in cash equal to $30.00, without interest thereon (the "Closing Amount"), plus (ii) one (1) contractual contingent value right ("CVR") representing the right to receive a contingent payment of $5.00, without interest thereon, in cash (the "Milestone Payment"), upon the achievement of certain regulatory milestones ("Milestone") set forth in the Contingent Value Rights Agreement between Parent and Continental Stock Transfer & Trust Company. F3: These securities were directly owned by The Jon F. Kayyem and Paige Gates-Kayyem Family Trust. Jon Faiz Kayyem is the trustee of The Jon F. Kayyem and Paige Gates-Kayyem Family Trust and he disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Child A | 0 |
Reported balance
After 2024-05-30 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2024-05-30 · Disposition to issuer · Disposed 25,000 · Balance 0 F1: Under the Agreement and Plan of Merger, dated January 22, 2024 (the "Merger Agreement"), by and among the Inhibrx, Inc. (the "Issuer"), Aventis Inc., a Pennsylvania corporation ("Parent") and wholly owned subsidiary of Sanofi, and Art Acquisition Sub, Inc., a Delaware corporation ("Merger Sub") and wholly owned subsidiary of Parent, following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on May 30, 2024, Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F2: In the Merger, each share of common stock of the Issuer that was outstanding immediately prior to the effective time of the Merger (the "Effective Time") (other than (A) the Issuer's common stock owned by the Issuer as treasury shares, (B) the Issuer's common stock owned by Parent or Merger Sub and (C) any dissenting shares), was automatically cancelled, extinguished and converted into the right to receive (i) an amount in cash equal to $30.00, without interest thereon (the "Closing Amount"), plus (ii) one (1) contractual contingent value right ("CVR") representing the right to receive a contingent payment of $5.00, without interest thereon, in cash (the "Milestone Payment"), upon the achievement of certain regulatory milestones ("Milestone") set forth in the Contingent Value Rights Agreement between Parent and Continental Stock Transfer & Trust Company. F4: These securities were held in a custodial account managed by the reporting person for the benefit of the reporting person's minor child, Child A. The reporting person disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Child B | 0 |
Reported balance
After 2024-05-30 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2024-05-30 · Disposition to issuer · Disposed 25,000 · Balance 0 F1: Under the Agreement and Plan of Merger, dated January 22, 2024 (the "Merger Agreement"), by and among the Inhibrx, Inc. (the "Issuer"), Aventis Inc., a Pennsylvania corporation ("Parent") and wholly owned subsidiary of Sanofi, and Art Acquisition Sub, Inc., a Delaware corporation ("Merger Sub") and wholly owned subsidiary of Parent, following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on May 30, 2024, Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F2: In the Merger, each share of common stock of the Issuer that was outstanding immediately prior to the effective time of the Merger (the "Effective Time") (other than (A) the Issuer's common stock owned by the Issuer as treasury shares, (B) the Issuer's common stock owned by Parent or Merger Sub and (C) any dissenting shares), was automatically cancelled, extinguished and converted into the right to receive (i) an amount in cash equal to $30.00, without interest thereon (the "Closing Amount"), plus (ii) one (1) contractual contingent value right ("CVR") representing the right to receive a contingent payment of $5.00, without interest thereon, in cash (the "Milestone Payment"), upon the achievement of certain regulatory milestones ("Milestone") set forth in the Contingent Value Rights Agreement between Parent and Continental Stock Transfer & Trust Company. F5: These securities were held in a custodial account managed by the reporting person for the benefit of the reporting person's minor child, Child B. The reporting person disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.52 · Expires 2028-11-26 | Direct | 0 |
Reported balance
After 2024-05-30 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-05-30 · Disposition to issuer · Disposed 17,259 · Balance 0 F1: Under the Agreement and Plan of Merger, dated January 22, 2024 (the "Merger Agreement"), by and among the Inhibrx, Inc. (the "Issuer"), Aventis Inc., a Pennsylvania corporation ("Parent") and wholly owned subsidiary of Sanofi, and Art Acquisition Sub, Inc., a Delaware corporation ("Merger Sub") and wholly owned subsidiary of Parent, following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on May 30, 2024, Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F8: This stock option was cancelled in the Merger and converted into the right to receive (A) an amount in cash, without interest and less any applicable withholding taxes, equal to the product of (x) the total number of shares of the Issuer's common stock subject to such stock options immediately prior to the Effective Time, multiplied by (y) the excess of (I) the Closing Amount over (II) the exercise price payable per share of the Issuer common stock under such option and (B) one (1) CVR for each share of the Issuer common stock subject to such stock option. F6: Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on November 26, 2019, with the balance having vested and have become exercisable in equal successive monthly installments for thirty-six (36) months thereafter. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.03 · Expires 2033-05-25 | Direct | 0 |
Reported balance
After 2024-05-30 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-05-30 · Disposition to issuer · Disposed 15,000 · Balance 0 F1: Under the Agreement and Plan of Merger, dated January 22, 2024 (the "Merger Agreement"), by and among the Inhibrx, Inc. (the "Issuer"), Aventis Inc., a Pennsylvania corporation ("Parent") and wholly owned subsidiary of Sanofi, and Art Acquisition Sub, Inc., a Delaware corporation ("Merger Sub") and wholly owned subsidiary of Parent, following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on May 30, 2024, Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F8: This stock option was cancelled in the Merger and converted into the right to receive (A) an amount in cash, without interest and less any applicable withholding taxes, equal to the product of (x) the total number of shares of the Issuer's common stock subject to such stock options immediately prior to the Effective Time, multiplied by (y) the excess of (I) the Closing Amount over (II) the exercise price payable per share of the Issuer common stock under such option and (B) one (1) CVR for each share of the Issuer common stock subject to such stock option. F7: Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on May 25, 2024, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.57 · Expires 2032-05-25 | Direct | 0 |
Reported balance
After 2024-05-30 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-05-30 · Disposition to issuer · Disposed 15,000 · Balance 0 F1: Under the Agreement and Plan of Merger, dated January 22, 2024 (the "Merger Agreement"), by and among the Inhibrx, Inc. (the "Issuer"), Aventis Inc., a Pennsylvania corporation ("Parent") and wholly owned subsidiary of Sanofi, and Art Acquisition Sub, Inc., a Delaware corporation ("Merger Sub") and wholly owned subsidiary of Parent, following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on May 30, 2024, Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F8: This stock option was cancelled in the Merger and converted into the right to receive (A) an amount in cash, without interest and less any applicable withholding taxes, equal to the product of (x) the total number of shares of the Issuer's common stock subject to such stock options immediately prior to the Effective Time, multiplied by (y) the excess of (I) the Closing Amount over (II) the exercise price payable per share of the Issuer common stock under such option and (B) one (1) CVR for each share of the Issuer common stock subject to such stock option. F9: Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on May 25, 2023, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.78 · Expires 2031-06-07 | Direct | 0 |
Reported balance
After 2024-05-30 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2024-05-30 · Disposition to issuer · Disposed 15,000 · Balance 0 F1: Under the Agreement and Plan of Merger, dated January 22, 2024 (the "Merger Agreement"), by and among the Inhibrx, Inc. (the "Issuer"), Aventis Inc., a Pennsylvania corporation ("Parent") and wholly owned subsidiary of Sanofi, and Art Acquisition Sub, Inc., a Delaware corporation ("Merger Sub") and wholly owned subsidiary of Parent, following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on May 30, 2024, Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F8: This stock option was cancelled in the Merger and converted into the right to receive (A) an amount in cash, without interest and less any applicable withholding taxes, equal to the product of (x) the total number of shares of the Issuer's common stock subject to such stock options immediately prior to the Effective Time, multiplied by (y) the excess of (I) the Closing Amount over (II) the exercise price payable per share of the Issuer common stock under such option and (B) one (1) CVR for each share of the Issuer common stock subject to such stock option. F10: Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on June 7, 2022, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Under the Agreement and Plan of Merger, dated January 22, 2024 (the "Merger Agreement"), by and among the Inhibrx, Inc. (the "Issuer"), Aventis Inc., a Pennsylvania corporation ("Parent") and wholly owned subsidiary of Sanofi, and Art Acquisition Sub, Inc., a Delaware corporation ("Merger Sub") and wholly owned subsidiary of Parent, following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on May 30, 2024, Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger").
F2: In the Merger, each share of common stock of the Issuer that was outstanding immediately prior to the effective time of the Merger (the "Effective Time") (other than (A) the Issuer's common stock owned by the Issuer as treasury shares, (B) the Issuer's common stock owned by Parent or Merger Sub and (C) any dissenting shares), was automatically cancelled, extinguished and converted into the right to receive (i) an amount in cash equal to $30.00, without interest thereon (the "Closing Amount"), plus (ii) one (1) contractual contingent value right ("CVR") representing the right to receive a contingent payment of $5.00, without interest thereon, in cash (the "Milestone Payment"), upon the achievement of certain regulatory milestones ("Milestone") set forth in the Contingent Value Rights Agreement between Parent and Continental Stock Transfer & Trust Company.
F3: These securities were directly owned by The Jon F. Kayyem and Paige Gates-Kayyem Family Trust. Jon Faiz Kayyem is the trustee of The Jon F. Kayyem and Paige Gates-Kayyem Family Trust and he disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein.
F4: These securities were held in a custodial account managed by the reporting person for the benefit of the reporting person's minor child, Child A. The reporting person disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein.
F5: These securities were held in a custodial account managed by the reporting person for the benefit of the reporting person's minor child, Child B. The reporting person disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein.
F6: Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on November 26, 2019, with the balance having vested and have become exercisable in equal successive monthly installments for thirty-six (36) months thereafter.
F7: Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on May 25, 2024, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter.
F8: This stock option was cancelled in the Merger and converted into the right to receive (A) an amount in cash, without interest and less any applicable withholding taxes, equal to the product of (x) the total number of shares of the Issuer's common stock subject to such stock options immediately prior to the Effective Time, multiplied by (y) the excess of (I) the Closing Amount over (II) the exercise price payable per share of the Issuer common stock under such option and (B) one (1) CVR for each share of the Issuer common stock subject to such stock option.
F9: Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on May 25, 2023, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter.
F10: Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on June 7, 2022, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 01, 2023 Filed Jan 4, 2023 23:20 UTC | BIODESIX INC BDSX · Entity 6053 | GrantRestricted Stock Units · Derivative | 62,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-000519 · form4.xml · derivative · entry 1 Kayyem Jon Faiz · CIK 0001366268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,833 Underlying: Common Stock · 62,500 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: These RSUs will vest in full on March 31, 2023, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. In the event the Reporting Person's continued service on the Board terminates other than for cause, these RSUs will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period. F2 · derivative.expiration_date: These RSUs will vest in full on March 31, 2023, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. In the event the Reporting Person's continued service on the Board terminates other than for cause, these RSUs will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period. Read SEC document |
| December 21, 2022 Filed Dec 22, 2022 21:31 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionRestricted Stock Units · Derivative | 31,619 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-046669 · form4.xml · derivative · entry 3 Kayyem Jon Faiz · CIK 0001366268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 31,619 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: These restricted stock units vested in full on December 5, 2022 and were settled in shares of Common Stock on December 21, 2022. These restricted stock units had no expiration date. F3 · derivative.expiration_date: These restricted stock units vested in full on December 5, 2022 and were settled in shares of Common Stock on December 21, 2022. These restricted stock units had no expiration date. Read SEC document |
| December 21, 2022 Filed Dec 22, 2022 21:31 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionCommon Stock | 31,619 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-22-046669 · form4.xml · nonDerivative · entry 1 Kayyem Jon Faiz · CIK 0001366268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,619 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| December 21, 2022 Filed Dec 22, 2022 21:04 UTC | Inhibrx, Inc. INBX · Entity 90351 | SaleCommon Stock | 1,959 | $27.61 | $54,087.79 |
DisclosureSEC source: 0001739614-22-000132 · wf-form4_167174304358342.xml · nonDerivative · entry 2 Kayyem Jon Faiz · CIK 0001366268 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By The Jon F. Kayyem and Paige Gates-Kayyem Family Trust Disclosed balance after: 3,233,801 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by The Jon F. Kayyem and Paige Gates-Kayyem Family Trust. F4 · price: The shares were sold in multiple transactions at prices ranging from $27.39 to $27.74, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: These securities are directly owned by The Jon F. Kayyem and Paige Gates-Kayyem Family Trust. Jon Faiz Kayyem is the trustee of The Jon F. Kayyem and Paige Gates-Kayyem Family Trust and he disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein. Read SEC document |
| December 21, 2022 Filed Dec 22, 2022 21:04 UTC | Inhibrx, Inc. INBX · Entity 90351 | SaleCommon Stock | 7,541 | $26.87 | $202,591.23 |
DisclosureSEC source: 0001739614-22-000132 · wf-form4_167174304358342.xml · nonDerivative · entry 1 Kayyem Jon Faiz · CIK 0001366268 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By The Jon F. Kayyem and Paige Gates-Kayyem Family Trust Disclosed balance after: 3,235,760 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by The Jon F. Kayyem and Paige Gates-Kayyem Family Trust. F2 · price: The shares were sold in multiple transactions at prices ranging from $26.385 to $27.38, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: These securities are directly owned by The Jon F. Kayyem and Paige Gates-Kayyem Family Trust. Jon Faiz Kayyem is the trustee of The Jon F. Kayyem and Paige Gates-Kayyem Family Trust and he disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein. Read SEC document |
| November 21, 2022 Filed Nov 21, 2022 23:02 UTC | BIODESIX INC BDSX · Entity 6053 | PurchaseCommon Stock | 173,913 | $1.15 | $199,999.95 |
DisclosureSEC source: 0001140361-22-042596 · form4.xml · nonDerivative · entry 1 Kayyem Jon Faiz · CIK 0001366268 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By The Jon Faiz Kayyem Revocable Trust Disclosed balance after: 173,913 F1 · ownership.nature: These securities are directly owned by The Jon Faiz Kayyem Revocable Trust, of which Jon Faiz Kayyem and his spouse serve as co-trustees. The reporting person disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein. Read SEC document |
| November 21, 2022 Filed Nov 22, 2022 21:42 UTC | Inhibrx, Inc. INBX · Entity 90351 | SaleCommon Stock | 6,767 | $30.12 | $203,819.33 |
DisclosureSEC source: 0001739614-22-000126 · wf-form4_166915334652304.xml · nonDerivative · entry 2 Kayyem Jon Faiz · CIK 0001366268 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By The Jon F. Kayyem and Paige Gates-Kayyem Family Trust Disclosed balance after: 3,243,301 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by The Jon F. Kayyem and Paige Gates-Kayyem Family Trust. F4 · price: The shares were sold in multiple transactions at prices ranging from $29.77 to $30.5115, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: These securities are directly owned by The Jon F. Kayyem and Paige Gates-Kayyem Family Trust. Jon Faiz Kayyem is the trustee of The Jon F. Kayyem and Paige Gates-Kayyem Family Trust and he disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein. Read SEC document |
| November 21, 2022 Filed Nov 22, 2022 21:42 UTC | Inhibrx, Inc. INBX · Entity 90351 | SaleCommon Stock | 2,733 | $29.33 | $80,153.15 |
DisclosureSEC source: 0001739614-22-000126 · wf-form4_166915334652304.xml · nonDerivative · entry 1 Kayyem Jon Faiz · CIK 0001366268 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By The Jon F. Kayyem and Paige Gates-Kayyem Family Trust Disclosed balance after: 3,250,068 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by The Jon F. Kayyem and Paige Gates-Kayyem Family Trust. F2 · price: The shares were sold in multiple transactions at prices ranging from $28.77 to $29.7697, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: These securities are directly owned by The Jon F. Kayyem and Paige Gates-Kayyem Family Trust. Jon Faiz Kayyem is the trustee of The Jon F. Kayyem and Paige Gates-Kayyem Family Trust and he disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein. Read SEC document |
| October 21, 2022 Filed Oct 24, 2022 20:36 UTC | Inhibrx, Inc. INBX · Entity 90351 | SaleCommon Stock | 5,928 | $30.58 | $181,254.53 |
DisclosureSEC source: 0001739614-22-000109 · wf-form4_166664378588834.xml · nonDerivative · entry 2 Kayyem Jon Faiz · CIK 0001366268 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By The Jon F. Kayyem and Paige Gates-Kayyem Family Trust Disclosed balance after: 3,252,801 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by The Jon F. Kayyem and Paige Gates-Kayyem Family Trust. F4 · price: The shares were sold in multiple transactions at prices ranging from $30.34 to $31.00, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: These securities are directly owned by The Jon F. Kayyem and Paige Gates-Kayyem Family Trust. Jon Faiz Kayyem is the trustee of The Jon F. Kayyem and Paige Gates-Kayyem Family Trust and he disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein. Read SEC document |
| October 21, 2022 Filed Oct 24, 2022 20:36 UTC | Inhibrx, Inc. INBX · Entity 90351 | SaleCommon Stock | 3,572 | $29.39 | $104,977.15 |
DisclosureSEC source: 0001739614-22-000109 · wf-form4_166664378588834.xml · nonDerivative · entry 1 Kayyem Jon Faiz · CIK 0001366268 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By The Jon F. Kayyem and Paige Gates-Kayyem Family Trust Disclosed balance after: 3,258,729 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by The Jon F. Kayyem and Paige Gates-Kayyem Family Trust. F2 · price: The shares were sold in multiple transactions at prices ranging from $29.14 to $29.96, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: These securities are directly owned by The Jon F. Kayyem and Paige Gates-Kayyem Family Trust. Jon Faiz Kayyem is the trustee of The Jon F. Kayyem and Paige Gates-Kayyem Family Trust and he disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein. Read SEC document |
| August 24, 2022 Filed Aug 25, 2022 20:20 UTC | Inhibrx, Inc. INBX · Entity 90351 | GiftCommon Stock | 11,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001739614-22-000093 · wf-form4_166145880183931.xml · nonDerivative · entry 1 Kayyem Jon Faiz · CIK 0001366268 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By The Jon F. Kayyem and Paige Gates-Kayyem Family Trust Disclosed balance after: 3,262,301 F1 · kind: This transaction involved a gift of 11,900 shares of Common Stock by The Jon F. Kayyem and Paige Gates-Kayyem Family Trust to a trust for the benefit of individuals not residing in the reporting person's household, to which the reporting person does not have a beneficial interest. F2 · ownership.nature: These securities are directly owned by The Jon F. Kayyem and Paige Gates-Kayyem Family Trust. Jon Faiz Kayyem is the trustee of The Jon F. Kayyem and Paige Gates-Kayyem Family Trust and he disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein. Read SEC document |
| August 05, 2022 Filed Aug 8, 2022 20:22 UTC | Inhibrx, Inc. INBX · Entity 90351 | GiftCommon Stock | 3,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001739614-22-000086 · wf-form4_165999008770441.xml · nonDerivative · entry 1 Kayyem Jon Faiz · CIK 0001366268 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By The Jon F. Kayyem and Paige Gates-Kayyem Family Trust Disclosed balance after: 3,274,201 F1 · kind: This transaction involved a gift of 3,400 shares of Common Stock by The Jon F. Kayyem and Paige Gates-Kayyem Family Trust. Of the shares gifted, 1,400 shares were gifted to individuals not residing in the reporting person's household, and 2,000 shares were gifted to a trust for the benefit of individuals not residing in the reporting person's household, in each case to which the reporting person does not have a beneficial interest. F2 · ownership.nature: These securities are directly owned by The Jon F. Kayyem and Paige Gates-Kayyem Family Trust. Jon Faiz Kayyem is the trustee of The Jon F. Kayyem and Paige Gates-Kayyem Family Trust and he disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein. Read SEC document |
| August 02, 2022 Filed Aug 2, 2022 20:52 UTC | Inhibrx, Inc. INBX · Entity 90351 | GiftCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001739614-22-000075 · wf-form4_165947352645392.xml · nonDerivative · entry 3 Kayyem Jon Faiz · CIK 0001366268 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Child B Disclosed balance after: 25,000 F4 · kind: This transaction involved a gift of 25,000 shares of Common Stock by The Jon F. Kayyem and Paige Gates-Kayyem Family Trust to a custodial account managed by the reporting person for the benefit of the reporting person's minor child, Child B. The reporting person disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein. Read SEC document |
| August 02, 2022 Filed Aug 2, 2022 20:52 UTC | Inhibrx, Inc. INBX · Entity 90351 | GiftCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001739614-22-000075 · wf-form4_165947352645392.xml · nonDerivative · entry 2 Kayyem Jon Faiz · CIK 0001366268 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Child A Disclosed balance after: 25,000 F3 · kind: This transaction involved a gift of 25,000 shares of Common Stock by The Jon F. Kayyem and Paige Gates-Kayyem Family Trust to a custodial account managed by the reporting person for the benefit of the reporting person's minor child, Child A. The reporting person disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein. Read SEC document |
| August 02, 2022 Filed Aug 2, 2022 20:52 UTC | Inhibrx, Inc. INBX · Entity 90351 | GiftCommon Stock | 118,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001739614-22-000075 · wf-form4_165947352645392.xml · nonDerivative · entry 1 Kayyem Jon Faiz · CIK 0001366268 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By The Jon F. Kayyem and Paige Gates-Kayyem Family Trust Disclosed balance after: 3,277,601 F1 · kind: This transaction involved a gift of 118,500 shares of Common Stock by The Jon F. Kayyem and Paige Gates-Kayyem Family Trust to the reporting person's children and other relatives. Of the shares gifted, 60,000 shares were gifted to the reporting person's adult children not residing in the reporting person's household, 3,400 shares were gifted to relatives not residing in the reporting person's household, and 5,100 shares were gifted to a trust for the benefit of relatives not residing in the reporting person's household, in each case to which the reporting person does not have a beneficial interest. F2 · ownership.nature: These securities are directly owned by The Jon F. Kayyem and Paige Gates-Kayyem Family Trust. Jon Faiz Kayyem is the trustee of The Jon F. Kayyem and Paige Gates-Kayyem Family Trust and he disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein. Read SEC document |
| May 25, 2022 Filed May 26, 2022 20:38 UTC | Inhibrx, Inc. INBX · Entity 90351 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $12.57 | $0.00 |
DisclosureSEC source: 0001739614-22-000065 · wf-form4_165359747904257.xml · derivative · entry 1 Kayyem Jon Faiz · CIK 0001366268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,259 Underlying: Common Stock · 15,000 shares Expires 2032-05-25 F1 · derivative.exercise_date: Twenty-five percent (25%) of the total shares subject to the stock option become exercisable on May 25, 2023, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter. Read SEC document |
| May 24, 2022 Filed May 26, 2022 20:15 UTC | BIODESIX INC BDSX · Entity 6053 | GrantRestricted Stock Units · Derivative | 83,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-020784 · form4.xml · derivative · entry 1 Kayyem Jon Faiz · CIK 0001366268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,333 Underlying: Common Stock · 83,333 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock and has no expiration date. F3 · shares: The Compensation Committee of the Issuer's Board of Directors also approved a grant to the Reporting Person, effective January 1, 2023, of an additional 62,500 RSUs that will vest in full on March 31, 2023, generally subject to the reporting person's continued service with the Issuer. In the event the reporting person's continued service on the Board terminates other than for cause, the option will vest on a prorated basis based on the number of full months of service the reporting person completed during the applicable vesting period. F2 · derivative.exercise_date: These RSUs will vest in full on March 31, 2023, generally subject to the reporting person's continued service with the Issuer. In the event the reporting person's continued service on the Board terminates other than for cause, the option will vest on a prorated basis based on the number of full months of service the reporting person completed during the applicable vesting period. F2 · derivative.expiration_date: These RSUs will vest in full on March 31, 2023, generally subject to the reporting person's continued service with the Issuer. In the event the reporting person's continued service on the Board terminates other than for cause, the option will vest on a prorated basis based on the number of full months of service the reporting person completed during the applicable vesting period. F3 · derivative.underlying_shares: The Compensation Committee of the Issuer's Board of Directors also approved a grant to the Reporting Person, effective January 1, 2023, of an additional 62,500 RSUs that will vest in full on March 31, 2023, generally subject to the reporting person's continued service with the Issuer. In the event the reporting person's continued service on the Board terminates other than for cause, the option will vest on a prorated basis based on the number of full months of service the reporting person completed during the applicable vesting period. F3 · balance_after: The Compensation Committee of the Issuer's Board of Directors also approved a grant to the Reporting Person, effective January 1, 2023, of an additional 62,500 RSUs that will vest in full on March 31, 2023, generally subject to the reporting person's continued service with the Issuer. In the event the reporting person's continued service on the Board terminates other than for cause, the option will vest on a prorated basis based on the number of full months of service the reporting person completed during the applicable vesting period. Read SEC document |
| December 07, 2021 Filed Dec 8, 2021 21:30 UTC | BIODESIX INC BDSX · Entity 6053 | GrantStock Options (Right to Buy) · Derivative | 27,038 | $0.00 Strike: $5.67 | $0.00 |
DisclosureSEC source: 0001140361-21-040848 · form4.xml · derivative · entry 3 Kayyem Jon Faiz · CIK 0001366268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,038 Underlying: Common Stock · 27,038 shares Expires 2031-12-06 F4 · derivative.exercise_date: This option will vest in full on March 31, 2022, subject to the reporting person's continued service on the Board through the applicable vesting date. In the event the reporting person's continued service on the Board terminates other than for cause, the option will vest on a prorated basis based on the number of full months of service the reporting person completed during the applicable vesting period. Read SEC document |
| December 06, 2021 Filed Dec 8, 2021 21:30 UTC | BIODESIX INC BDSX · Entity 6053 | GrantStock Options (Right to Buy) · Derivative | 50,368 | $0.00 Strike: $5.93 | $0.00 |
DisclosureSEC source: 0001140361-21-040848 · form4.xml · derivative · entry 2 Kayyem Jon Faiz · CIK 0001366268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,368 Underlying: Common Stock · 50,368 shares Expires 2031-12-05 F3 · derivative.exercise_date: This option vests 40% on December 6, 2023, and the remaining 60% in 36 successive, equal monthly installments measured from December 6, 2023, generally subject to the reporting person's continued service on the Board through the applicable vesting date. Read SEC document |
| December 06, 2021 Filed Dec 8, 2021 21:30 UTC | BIODESIX INC BDSX · Entity 6053 | GrantRestricted Stock Units · Derivative | 31,619 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-21-040848 · form4.xml · derivative · entry 1 Kayyem Jon Faiz · CIK 0001366268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,619 Underlying: Common Stock · 31,619 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: These restricted stock units will vest in full on December 6, 2022, generally subject to the reporting person's continued service on the Issuer's board of directors (the "Board") through the applicable vesting date, and have no expiration date. F2 · derivative.expiration_date: These restricted stock units will vest in full on December 6, 2022, generally subject to the reporting person's continued service on the Issuer's board of directors (the "Board") through the applicable vesting date, and have no expiration date. Read SEC document |
| June 07, 2021 Filed Jun 8, 2021 21:20 UTC | Inhibrx, Inc. INBX · Entity 90351 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $24.78 | $0.00 |
DisclosureSEC source: 0001739614-21-000071 · wf-form4_162318722240649.xml · derivative · entry 1 Kayyem Jon Faiz · CIK 0001366268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,259 Underlying: Common Stock · 15,000 shares Expires 2031-06-07 F1 · derivative.exercise_date: (1) Twenty-five percent (25%) of the total shares subject to the June 7, 2022, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter. Read SEC document |
| February 02, 2018 Filed Feb 6, 2018 20:24 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | SaleCommon Stock | 148 | $5.13 | $759.24 |
DisclosureSEC source: 0001487371-18-000017 · wf-form4_151796663557707.xml · nonDerivative · entry 1 Kayyem Jon Faiz · CIK 0001366268 · SVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,622 F1 · kind: The shares were sold pursuant to pre-established trading instructions solely to satisfy tax withholding obligations in connection with the partial vesting of previously granted restricted stock units. Read SEC document |
| December 04, 2017 Filed Dec 6, 2017 18:20 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | SaleCommon Stock | 135 | $4.70 | $634.50 |
DisclosureSEC source: 0001487371-17-000251 · wf-form4_151260242389809.xml · nonDerivative · entry 1 Kayyem Jon Faiz · CIK 0001366268 · SVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,770 F1 · kind: The shares were sold pursuant to pre-established trading instructions solely to satisfy tax withholding obligations in connection with the partial vesting of previously granted restricted stock units. Read SEC document |
| November 20, 2017 Filed Nov 21, 2017 18:04 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | SaleCommon Stock | 1,269 | $4.74 | $6,015.06 |
DisclosureSEC source: 0001487371-17-000240 · wf-form4_151130542745787.xml · nonDerivative · entry 1 Kayyem Jon Faiz · CIK 0001366268 · SVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,905 F1 · kind: The shares were sold pursuant to pre-established trading instructions solely to satisfy tax withholding obligations in connection with the partial vesting of previously granted restricted stock units. Read SEC document |
| November 02, 2017 Filed Nov 3, 2017 19:50 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | SaleCommon Stock | 135 | $7.24 | $977.40 |
DisclosureSEC source: 0001487371-17-000227 · wf-form4_150975298830344.xml · nonDerivative · entry 1 Kayyem Jon Faiz · CIK 0001366268 · SVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,174 F1 · kind: The shares were sold pursuant to pre-established trading instructions solely to satisfy tax withholding obligations in connection with the partial vesting of previously granted restricted stock units. Read SEC document |
| September 05, 2017 Filed Sep 6, 2017 18:08 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | SaleCommon Stock | 133 | $9.75 | $1,296.75 |
DisclosureSEC source: 0001487371-17-000190 · wf-form4_150473566663948.xml · nonDerivative · entry 1 Kayyem Jon Faiz · CIK 0001366268 · SVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,309 F1 · kind: The shares were sold pursuant to pre-established trading instructions solely to satisfy tax withholding obligations in connection with the partial vesting of previously granted restricted stock units. Read SEC document |
| August 21, 2017 Filed Aug 23, 2017 14:36 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | SaleCommon Stock | 1,277 | $9.45 | $12,067.65 |
DisclosureSEC source: 0001487371-17-000181 · wf-form4_150351337372147.xml · nonDerivative · entry 1 Kayyem Jon Faiz · CIK 0001366268 · SVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,442 F1 · kind: The shares were sold pursuant to pre-established trading instructions solely to satisfy tax withholding obligations in connection with the partial vesting of previously granted restricted stock units. Read SEC document |
| August 02, 2017 Filed Aug 4, 2017 13:25 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | SaleCommon Stock | 138 | $10.33 | $1,425.54 |
DisclosureSEC source: 0001487371-17-000164 · wf-form4_150186751312935.xml · nonDerivative · entry 1 Kayyem Jon Faiz · CIK 0001366268 · SVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,719 F1 · kind: The shares were sold pursuant to pre-established trading instructions solely to satisfy tax withholding obligations in connection with the partial vesting of previously granted restricted stock units. Read SEC document |
| June 02, 2017 Filed Jun 5, 2017 16:58 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | SaleCommon Stock | 132 | $12.89 | $1,701.48 |
DisclosureSEC source: 0001487371-17-000138 · wf-form4_149669630909881.xml · nonDerivative · entry 1 Kayyem Jon Faiz · CIK 0001366268 · SVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,857 F1 · kind: The shares were sold pursuant to pre-established trading instructions solely to satisfy tax withholding obligations in connection with the partial vesting of previously granted restricted stock units. Read SEC document |
| May 19, 2017 Filed May 23, 2017 16:52 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | SaleCommon Stock | 1,265 | $12.89 | $16,305.85 |
DisclosureSEC source: 0001487371-17-000115 · wf-form4_149557273185034.xml · nonDerivative · entry 1 Kayyem Jon Faiz · CIK 0001366268 · SVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,989 F1 · kind: The shares were sold pursuant to pre-established trading instructions solely to satisfy tax withholding obligations in connection with the partial vesting of previously granted restricted stock units. Read SEC document |
| May 02, 2017 Filed May 4, 2017 17:10 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | SaleCommon Stock | 133 | $13.34 | $1,774.22 |
DisclosureSEC source: 0001487371-17-000100 · wf-form4_149393224260734.xml · nonDerivative · entry 1 Kayyem Jon Faiz · CIK 0001366268 · SVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,254 F1 · kind: The shares were sold pursuant to pre-established trading instructions solely to satisfy tax withholding obligations in connection with the partial vesting of previously granted restricted stock units. Read SEC document |
| March 07, 2017 Filed Mar 9, 2017 19:53 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | SaleCommon Stock | 311 | $12.18 | $3,787.98 |
DisclosureSEC source: 0001487371-17-000074 · wf-form4_148910719693921.xml · nonDerivative · entry 1 Kayyem Jon Faiz · CIK 0001366268 · SVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,387 F1 · kind: The shares were sold pursuant to pre-established trading instructions solely to satisfy tax withholding obligations in connection with the partial vesting of previously granted restricted stock units. Read SEC document |
| March 03, 2017 Filed Mar 3, 2017 19:13 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | SaleCommon Stock | 131 | $12.29 | $1,609.99 |
DisclosureSEC source: 0001487371-17-000070 · wf-form4_148858637184731.xml · nonDerivative · entry 1 Kayyem Jon Faiz · CIK 0001366268 · SVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,698 F1 · kind: The shares were sold pursuant to pre-established trading instructions solely to satisfy tax withholding obligations in connection with the partial vesting of previously granted restricted stock units. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 19:19 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | GrantMarket Stock Units · Derivative | 16,250 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001487371-17-000050 · wf-form4_148798196031501.xml · derivative · entry 5 Kayyem Jon Faiz · CIK 0001366268 · SVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,250 Underlying: Common Stock · 16,250 shares Expires not disclosed F3 · shares: Each market stock unit ("MSU") represents the contingent right to receive, following vesting, between 0% and 200% of one share of the Issuer's common stock, subject to the level of achievement of applicable performance conditions. The resulting number of shares acquired upon vesting of the MSUs, if any, is based on the Issuer's total shareholder return for each performance period as compared to the Nasdaq Composite Index. F4 · derivative.exercise_date: The MSUs vest in three equal installments, on each of December 31, 2017, December 31, 2018, and December 31, 2019; provided that, at the end of the second and third annual performance periods, the Reporting Person is eligible to receive any shares that were not earned in the first and second annual performance periods to the extent that the Issuer's two-year or three-year total shareholder return, as applicable, exceeds the prior performance results as compared to the Nasdaq Composite Index. F4 · derivative.expiration_date: The MSUs vest in three equal installments, on each of December 31, 2017, December 31, 2018, and December 31, 2019; provided that, at the end of the second and third annual performance periods, the Reporting Person is eligible to receive any shares that were not earned in the first and second annual performance periods to the extent that the Issuer's two-year or three-year total shareholder return, as applicable, exceeds the prior performance results as compared to the Nasdaq Composite Index. F3 · derivative.underlying_shares: Each market stock unit ("MSU") represents the contingent right to receive, following vesting, between 0% and 200% of one share of the Issuer's common stock, subject to the level of achievement of applicable performance conditions. The resulting number of shares acquired upon vesting of the MSUs, if any, is based on the Issuer's total shareholder return for each performance period as compared to the Nasdaq Composite Index. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 19:19 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | GrantCommon Stock | 48,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001487371-17-000050 · wf-form4_148798196031501.xml · nonDerivative · entry 1 Kayyem Jon Faiz · CIK 0001366268 · SVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,829 F1 · shares: The amount reported reflects restricted stock units granted to the reporting person pursuant to the Issuer's 2010 Equity Incentive Plan. The restricted stock units vest 25% on February 22, 2018 and the remaining shares subject to such award vest in 12 equal quarterly installments thereafter. Read SEC document |
| February 21, 2017 Filed Feb 21, 2017 20:02 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | SaleCommon Stock | 5,250 | $10.08 | $52,920.00 |
DisclosureSEC source: 0001487371-17-000040 · wf-form4_148772536212075.xml · nonDerivative · entry 1 Kayyem Jon Faiz · CIK 0001366268 · SVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,079 F1 · kind: The shares were sold pursuant to pre-established trading instructions solely to satisfy tax withholding obligations in connection with the partial vesting of previously granted restricted stock units. Read SEC document |
| February 02, 2017 Filed Feb 3, 2017 17:46 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | SaleCommon Stock | 131 | $11.58 | $1,516.98 |
DisclosureSEC source: 0001487371-17-000022 · wf-form4_148616195985624.xml · nonDerivative · entry 1 Kayyem Jon Faiz · CIK 0001366268 · SVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,329 F1 · kind: The shares were sold pursuant to pre-established trading instructions solely to satisfy tax withholding obligations in connection with the partial vesting of previously granted restricted stock units. Read SEC document |
| January 19, 2017 Filed Jan 20, 2017 18:49 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | Exercise / conversionMarket Stock Units · Derivative | 5,927 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001487371-17-000013 · wf-form4_148495613948717.xml · derivative · entry 8 Kayyem Jon Faiz · CIK 0001366268 · SVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,853 Underlying: Common Stock · 5,927 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · shares: Each MSU represents the contingent right to receive, following vesting, between 0% and 200% of one share of the Issuer's common stock, subject to the level of achievement of applicable performance conditions. The resulting number of shares acquired upon vesting of the MSUs, if any, is based on the Issuer's total shareholder return for each performance period as compared to the Nasdaq Composite Index. F6 · derivative.exercise_date: The MSUs vest in three equal installments, on each of December 31, 2016, December 31, 2017, and December 31, 2018; provided that, at the end of the second and third annual performance periods, the Reporting Person is eligible to receive any shares that were not earned in the first and second annual performance periods to the extent that the Issuer's two-year or three-year total shareholder return, as applicable, exceeds the prior performance results as compared to the Nasdaq Composite Index. F6 · derivative.expiration_date: The MSUs vest in three equal installments, on each of December 31, 2016, December 31, 2017, and December 31, 2018; provided that, at the end of the second and third annual performance periods, the Reporting Person is eligible to receive any shares that were not earned in the first and second annual performance periods to the extent that the Issuer's two-year or three-year total shareholder return, as applicable, exceeds the prior performance results as compared to the Nasdaq Composite Index. F4 · derivative.underlying_shares: Each MSU represents the contingent right to receive, following vesting, between 0% and 200% of one share of the Issuer's common stock, subject to the level of achievement of applicable performance conditions. The resulting number of shares acquired upon vesting of the MSUs, if any, is based on the Issuer's total shareholder return for each performance period as compared to the Nasdaq Composite Index. Read SEC document |
| January 19, 2017 Filed Jan 20, 2017 18:49 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | Exercise / conversionMarket Stock Units · Derivative | 2,096 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001487371-17-000013 · wf-form4_148495613948717.xml · derivative · entry 7 Kayyem Jon Faiz · CIK 0001366268 · SVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,295 Underlying: Common Stock · 2,096 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · shares: Each MSU represents the contingent right to receive, following vesting, between 0% and 200% of one share of the Issuer's common stock, subject to the level of achievement of applicable performance conditions. The resulting number of shares acquired upon vesting of the MSUs, if any, is based on the Issuer's total shareholder return for each performance period as compared to the Nasdaq Composite Index. F5 · derivative.exercise_date: The MSUs vest in three equal installments, on each of December 31, 2015, December 31, 2016, and December 31, 2017; provided that, at the end of the second and third annual performance periods, the Reporting Person is eligible to receive any shares that were not earned in the first and second annual performance periods to the extent that the Issuer's two-year or three-year total shareholder return, as applicable, exceeds the prior performance results as compared to the Nasdaq Composite Index. F5 · derivative.expiration_date: The MSUs vest in three equal installments, on each of December 31, 2015, December 31, 2016, and December 31, 2017; provided that, at the end of the second and third annual performance periods, the Reporting Person is eligible to receive any shares that were not earned in the first and second annual performance periods to the extent that the Issuer's two-year or three-year total shareholder return, as applicable, exceeds the prior performance results as compared to the Nasdaq Composite Index. F4 · derivative.underlying_shares: Each MSU represents the contingent right to receive, following vesting, between 0% and 200% of one share of the Issuer's common stock, subject to the level of achievement of applicable performance conditions. The resulting number of shares acquired upon vesting of the MSUs, if any, is based on the Issuer's total shareholder return for each performance period as compared to the Nasdaq Composite Index. Read SEC document |
| January 19, 2017 Filed Jan 20, 2017 18:49 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | SaleCommon Stock | 5,718 | $12.47 | $71,303.46 |
DisclosureSEC source: 0001487371-17-000013 · wf-form4_148495613948717.xml · nonDerivative · entry 3 Kayyem Jon Faiz · CIK 0001366268 · SVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,460 F2 · kind: The shares were sold pursuant to pre-established trading instructions solely to satisfy tax withholding obligations in connection with the partial vesting of previously granted MSUs. Read SEC document |
| January 19, 2017 Filed Jan 20, 2017 18:49 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | Exercise / conversionCommon Stock | 11,535 | $0.00 | $0.00 |
DisclosureSEC source: 0001487371-17-000013 · wf-form4_148495613948717.xml · nonDerivative · entry 2 Kayyem Jon Faiz · CIK 0001366268 · SVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,178 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Based on actual achievement for the one-year performance period, the recipient was issued 194.6% of the market stock units ("MSUs") which vested as of December 31, 2016. Read SEC document |
| January 19, 2017 Filed Jan 20, 2017 18:49 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | Exercise / conversionCommon Stock | 2,096 | $0.00 | $0.00 |
DisclosureSEC source: 0001487371-17-000013 · wf-form4_148495613948717.xml · nonDerivative · entry 1 Kayyem Jon Faiz · CIK 0001366268 · SVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,643 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 07, 2016 Filed Dec 9, 2016 17:59 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | SaleCommon Stock | 313 | $11.08 | $3,468.04 |
DisclosureSEC source: 0001487371-16-000398 · wf-form4_148132436210986.xml · nonDerivative · entry 1 Kayyem Jon Faiz · CIK 0001366268 · SVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,547 F1 · kind: The shares were sold pursuant to pre-established trading instructions solely to satisfy tax withholding obligations in connection with the partial vesting of previously granted restricted stock units. Read SEC document |
| December 02, 2016 Filed Dec 6, 2016 17:58 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | SaleCommon Stock | 132 | $11.30 | $1,491.60 |
DisclosureSEC source: 0001487371-16-000392 · wf-form4_148106512430588.xml · nonDerivative · entry 1 Kayyem Jon Faiz · CIK 0001366268 · SVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,860 F1 · kind: The shares were sold pursuant to pre-established trading instructions solely to satisfy tax withholding obligations in connection with the partial vesting of previously granted restricted stock units. Read SEC document |
| November 02, 2016 Filed Nov 4, 2016 17:37 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | SaleCommon Stock | 135 | $10.30 | $1,390.50 |
DisclosureSEC source: 0001487371-16-000376 · wf-form4_147829545168109.xml · nonDerivative · entry 1 Kayyem Jon Faiz · CIK 0001366268 · SVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,992 F1 · kind: The shares were sold pursuant to pre-established trading instructions solely to satisfy tax withholding obligations in connection with the partial vesting of previously granted restricted stock units. Read SEC document |
| September 07, 2016 Filed Sep 9, 2016 18:36 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | SaleCommon Stock | 310 | $8.69 | $2,693.90 |
DisclosureSEC source: 0001487371-16-000357 · wf-form4_147346056801196.xml · nonDerivative · entry 1 Kayyem Jon Faiz · CIK 0001366268 · SVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,127 F1 · kind: The shares were sold pursuant to pre-established trading instructions solely to satisfy tax withholding obligations in connection with the partial vesting of previously granted restricted stock units. Read SEC document |
| September 02, 2016 Filed Sep 6, 2016 18:02 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | SaleCommon Stock | 133 | $8.62 | $1,146.46 |
DisclosureSEC source: 0001487371-16-000347 · wf-form4_147319935650677.xml · nonDerivative · entry 1 Kayyem Jon Faiz · CIK 0001366268 · SVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,437 F1 · kind: The shares were sold pursuant to pre-established trading instructions solely to satisfy tax withholding obligations in connection with the partial vesting of previously granted restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.